TY - JOUR
T1 - Cognitive disorders in epilepsy II
T2 - Clinical targets, indications and selection of test instruments
AU - Helmstaedter, C.
AU - Sadat-Hossieny, Z.
AU - Kanner, A. M.
AU - Meador, K. J.
N1 - Funding Information:
Christoph Helmstaedter has received grants from the EU, travel support by Desitin, honoraries for talks, counseling, and advisory boards by GW pharmaceuticals, Eisai, UCB pharma and Precisis, as well as license fees by EISAI, UCB pharma and Precisis. Dr. Sadat-Hossieny has no disclosures. Dr. Kanner has received honoraria from Eisai and Neuropace. Dr. Meador has received research support from the National Institutes of Health and Sunovion Pharmaceuticals, and travel support from Eisai. The Epilepsy Study Consortium pays Dr Meador’s university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, and UCB Pharma.
PY - 2020/12
Y1 - 2020/12
N2 - This is the second of two narrative reviews on cognitive disorders in epilepsy (companion manuscript: Cognitive disorders in epilepsy I: Clinical experience, real-world evidence and recommendations). Its focus is on the clinical targets, indications, and the selection of neuropsychological test instruments. Cognitive assessment has become an essential tool for the diagnosis and outcome control in the clinical management of epilepsy. The diagnostics of basic and higher brain functions can provide valuable information on lateralized and localized brain dysfunctions associated with epilepsy, its underlying pathologies and treatment. In addition to the detection or verification of deficits, neuropsychology reveals the patient's cognitive strengths and, thus, information about the patient reserve capacities for functional restitution and compensation. Neuropsychology is an integral part of diagnostic evaluations mainly in the context of epilepsy surgery to avoid new or additional damage to preexisting neurocognitive impairments. In addition and increasingly, neuropsychology is being used as a tool for monitoring of the disease and its underlying pathologies, and it is suited for the quality and outcome control of pharmacological or other non-invasive medical intervention. This narrative review summarizes the present state of neuropsychological assessments in epilepsy, reveals diagnostic gaps, and shows the great need for education, homogenization, translation and standardization of instruments.
AB - This is the second of two narrative reviews on cognitive disorders in epilepsy (companion manuscript: Cognitive disorders in epilepsy I: Clinical experience, real-world evidence and recommendations). Its focus is on the clinical targets, indications, and the selection of neuropsychological test instruments. Cognitive assessment has become an essential tool for the diagnosis and outcome control in the clinical management of epilepsy. The diagnostics of basic and higher brain functions can provide valuable information on lateralized and localized brain dysfunctions associated with epilepsy, its underlying pathologies and treatment. In addition to the detection or verification of deficits, neuropsychology reveals the patient's cognitive strengths and, thus, information about the patient reserve capacities for functional restitution and compensation. Neuropsychology is an integral part of diagnostic evaluations mainly in the context of epilepsy surgery to avoid new or additional damage to preexisting neurocognitive impairments. In addition and increasingly, neuropsychology is being used as a tool for monitoring of the disease and its underlying pathologies, and it is suited for the quality and outcome control of pharmacological or other non-invasive medical intervention. This narrative review summarizes the present state of neuropsychological assessments in epilepsy, reveals diagnostic gaps, and shows the great need for education, homogenization, translation and standardization of instruments.
KW - Anticonvulsants
KW - Assessment
KW - Cognition
KW - Epilepsy
KW - Epilepsy surgery
KW - Neuropsychology
UR - http://www.scopus.com/inward/record.url?scp=85096396973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096396973&partnerID=8YFLogxK
U2 - 10.1016/j.seizure.2020.09.031
DO - 10.1016/j.seizure.2020.09.031
M3 - Review article
C2 - 33172763
AN - SCOPUS:85096396973
VL - 83
SP - 223
EP - 231
JO - Seizure : the journal of the British Epilepsy Association
JF - Seizure : the journal of the British Epilepsy Association
SN - 1059-1311
ER -